Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
Type:
Grant
Filed:
October 28, 2019
Date of Patent:
March 24, 2020
Assignee:
Caribou Biosciences, Inc.
Inventors:
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
Type:
Grant
Filed:
September 26, 2018
Date of Patent:
March 17, 2020
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Guangping Gao, James M. Wilson, Mauricio R. Alvira
Abstract: The present disclosure relates to engineered cells that include genetic alterations leading to up- or down-regulation of certain genes in the cells for improved production of a recombinant protein. Also provided are methods of preparing and using such cells.
Abstract: The invention provides recombinant adenovirus (rAd) and rAd vectors comprising a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such rAd and rAd vectors.
Type:
Grant
Filed:
April 12, 2016
Date of Patent:
February 25, 2020
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Kerstin Wunderlich, Jerôme H. H. V. Custers, Jort Vellinga, Barbara Petronella Sanders
Abstract: Recombinant bacterial cells are provided that comprise a stable non-canonical amino acid translation pathway. In some aspects, the bacteria comprise nucleic acids encoding a non-canonical amino acid translation pathway (e.g., a tRNA for incorporation of a non-canonical amino acid, such selenocysteine); a marker polypeptide that includes the non-canonical amino acid. Recombinant tRNA and selection marker coding sequences are likewise provided.
Type:
Grant
Filed:
December 15, 2016
Date of Patent:
February 11, 2020
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.
Type:
Grant
Filed:
February 26, 2014
Date of Patent:
February 4, 2020
Assignee:
President and Fellows of Harvard College
Inventors:
George M. Church, Srivatsan Raman, Noah D. Taylor, Jameson Rogers
Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules such as chikungunya viral proteins, such as chikungunya envelope protein E1.
Abstract: This disclosure relates to methods of diagnosing and predicting renal disease, using one, two, or more biomarkers, including sTN-FR1, sTNFR2, sFAS, TNF, and IL-6.
Type:
Grant
Filed:
September 21, 2017
Date of Patent:
November 26, 2019
Assignee:
Joslin Diabetes Center, Inc.
Inventors:
Monika A. Niewczas, Andrzej S. Krolewski
Abstract: The present invention relates to a nucleic acid construct comprising: a nucleic acid sequence encoding an ice structuring protein (ISP) comprising the sequence set out in SEQ ID NO: 1 or a sequence at least 80% identical thereto or comprising the sequence set out in amino acids 21 to 261 of SEQ ID NO: 1 or a sequence at least 80% identical thereto; and, linked operably thereto, control sequences permitting expression of the nucleic acid sequence in a filamentous fungal host cell. The construct may be used in a method for the production of an ISP, wherein the ISP is expressed in a filamentous fungal host cell.
Type:
Grant
Filed:
December 2, 2014
Date of Patent:
November 26, 2019
Assignee:
DSM IP ASSETS B.V.
Inventors:
René Marcel De Jong, Petrus Jacobus Theodorus Dekker
Abstract: The present disclosure relates to a novel use of EI24, and provides a novel use of EI24 involved in the improvement of EGFR-TKI drug resistance by inhibiting IGF-1R signaling. According to the present disclosure, the presence or absence of resistance to anti-cancer drugs may be determined by detecting an expression level of EI24. In addition, resistance to anti-cancer drugs may be inhibited, delayed, or improved using EI24 or an activating agent thereof. Moreover, by regulating a pathway of EI24-mediated resistance to anti-cancer drugs, the efficacy of existing anti-cancer drugs may be enhanced, and resistance to anti-cancer drugs may be inhibited, delayed, or improved.
Type:
Grant
Filed:
March 14, 2017
Date of Patent:
November 19, 2019
Assignee:
University-Industry Foundation, Yonsei University
Inventors:
Han Woong Lee, Jung-Min Choi, Byoung Chul Cho, Yu-Ra Choi, Ji-Young Jang, Hye Ryun Kim
Abstract: The invention relates to the use of microRNA 29 and precursors and mimics thereof for the modulation of tendon injury and the biomechanical properties of tendon. In particular, the invention derives from the finding that synthesis of type 1 collagen in tenocytes is less sensitive to miR-29 than is synthesis of type 3 collagen, thus enabling the balance between the collagen subtypes to be modulated in favour of type 1 collagen, mitigating reduction in biomechanical properties during healing.
Type:
Grant
Filed:
January 25, 2018
Date of Patent:
November 12, 2019
Inventors:
Derek Stewart Gilchrist, Neal Lindsay Millar
Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
Type:
Grant
Filed:
May 22, 2019
Date of Patent:
October 29, 2019
Assignee:
Caribou Biosciences, Inc.
Inventors:
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Abstract: An object is to provide a signal peptide that can secrete a heterologous polypeptide with high efficiency outside the bacterial cell in a bacterium of the genus Bifidobacterium, an expression cassette that can secrete a heterologous polypeptide with high efficiency outside the bacterial cell, a heterologous polypeptide expression vector, a bacterium of the genus Bifidobacterium capable of secreting a heterologous polypeptide. Means for attaining the object is a bacterium of the genus Bifidobacterium transformed by a vector having an expression cassette sequentially comprising a promoter DNA functioning in a bacterium of the genus Bifidobacterium, a DNA encoding the secretory signal peptide, a DNA encoding a scFv antibody having an antitumor activity, and a terminator DNA functioning in the bacterium of the genus Bifidobacterium; and capable of secreting the scFv antibody with high efficiency outside the bacterial cell.
Abstract: The present invention provides genetically modified eukaryotic host cells that produce isoprenoid precursors or isoprenoid compounds. A subject genetically modified host cell comprises increased activity levels of one or more of mevalonate pathway enzymes, increased levels of prenyltransferase activity, and decreased levels of squalene synthase activity. Methods are provided for the production of an isoprenoid compound or an isoprenoid precursor in a subject genetically modified eukaryotic host cell. The methods generally involve culturing a subject genetically modified host cell under conditions that promote production of high levels of an isoprenoid or isoprenoid precursor compound.
Type:
Grant
Filed:
October 2, 2017
Date of Patent:
October 8, 2019
Assignee:
The Regents of the University of California
Inventors:
Jay D. Keasling, James Kirby, Eric M. Paradise
Abstract: The present invention relates to immortalized chicken embryo fibroblasts, to cell cultures comprising such immortalized cells, to vaccines comprising such cells, to methods for the propagation of avian viruses on such cells, and to methods for the preparation of such cells and such vaccines.
Abstract: The present invention provides a method for increasing the expression of MAFA in cells expressing markers characteristic of the pancreatic endocrine lineage comprising the steps of culturing the cells expressing markers characteristic of the pancreatic endocrine lineage in medium comprising a sufficient amount of a cyclin-dependent kinase inhibitor to cause an increase in expression of MAFA.